ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

BeiGene ADR is working on a consolidation with a 248.16 entry. See if the stock can clear the breakout price in volume at ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

The FDA has approved BeiGene’s Tevimbra (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of unresectable or metastatic ...

BeiGene has said it intends to resubmit the drug for use by NHS Scotland. The recommendations come 10 months after Brukinsa was approved by the Medicines and Healthcare products Regulatory Agency ...

28,064 people played the daily Crossword recently. Can you solve it faster than others?28,064 people played the daily Crossword recently. Can you solve it faster than others? Warren Buffett Sends ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.